Prime Medicine (PRME) Retained Earnings (2021 - 2026)
Prime Medicine posted quarterly Retained Earnings of -$1000.0 for Q1 2026, up 100.0% year-on-year from -$500.0 in Q1 2025, and down 101.22% on a QoQ basis from $82000.0 in Q4 2025.
Prime Medicine (PRME) has 6 years of Retained Earnings data on file, last reported at -$1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 100.0% year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at -$1000.0 (up 100.0% YoY), and the FY2025 full-year result was $82000.0, up 8100.0% from the prior year.
- Retained Earnings for Q1 2026 stood at -$1000.0, down from $82000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $82000.0 in Q4 2025 and bottomed at -$842.3 million in Q3 2025.
- The 5-year median for Retained Earnings is -$253.9 million (2022), against an average of -$312.6 million.
- Peak annual rise in Retained Earnings reached 8100.0% in 2025, while the deepest fall reached 777900.0% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$384000.0 in 2022, then tumbled by 127850.52% to -$491.3 million in 2023, then jumped by 100.0% to $1000.0 in 2024, then surged by 8100.0% to $82000.0 in 2025, then slumped by 101.22% to -$1000.0 in 2026.
- The last three Retained Earnings figures came in at -$1000.0 (Q1 2026), $82000.0 (Q4 2025), and -$842.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | 82,000.00 |
| Sep 30, 2025 | -842.30 Mn |
| Jun 30, 2025 | -791.70 Mn |
| Mar 31, 2025 | -739.10 Mn |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -644.94 Mn |
| Jun 30, 2024 | -592.42 Mn |
| Mar 31, 2024 | -95,000.00 |
| Dec 31, 2023 | -491.33 Mn |
| Sep 30, 2023 | -149,000.00 |
| Jun 30, 2023 | -268,000.00 |
| Mar 31, 2023 | -332.60 Mn |
| Dec 31, 2022 | -384,000.00 |
| Sep 30, 2022 | -253.91 Mn |
| Dec 31, 2021 | -171.38 Mn |